Presentation and Panel particulars are beneath:
- Presentation Replace on Antibody Biopolymer Conjugates: Optimizing Immediacy and Sturdiness
Time:3:30 PM CT
Presenter:Mark Barakat , M.D., FASRS, Scientific Assistant Professor of Ophthalmology, College of Arizona Faculty of Medication “Phoenix ; Founder and Director of Analysis, Retina Macula Institute of Arizona; Medical Director, Spectra Eye Institute - Panel The Way forward for Retinal Therapeutics
Time:6:30 PM CT
Kodiak Panelist:Victor Perlroth , M.D., Chairman and Chief Govt Officer
Slides of the presentation shall be made accessible on the “Events and Presentations” part of Kodiak’s web site at http://ir.kodiak.com/ firstly of the presentation.
About Kodiak Sciences Inc .
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical firm dedicated to researching, growing, and commercializing transformative therapeutics to deal with a broad spectrum of retinal illnesses. We’re centered on bringing new science to the design and manufacture of subsequent era retinal medicines to stop and deal with the main causes of blindness globally. Our ABCD Platform™ makes use of molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been on the core of Kodiak’s discovery engine. We’re growing a portfolio of three medical packages, two of that are late-stage immediately and derived from our ABCD Platform and one which is platform-independent and which we consider can progress quickly into pivotal research.
Kodiak’s lead investigational drugs, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate underneath improvement for the remedy of excessive prevalence retinal vascular illnesses. Tarcocimab is at present being studied in two Part 3 medical trials, GLOW2 in sufferers with diabetic retinopathy and DAYBREAK in sufferers with moist AMD (NASDAQ:). Each research are actively enrolling sufferers.
KSI-501 is our second investigational drugs, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit each IL-6 mediated irritation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the remedy of excessive prevalence retinal vascular illnesses to deal with the unmet wants of prolonged sturdiness and concentrating on a number of illness biologies for differentiated efficacy. The Part 3 DAYBREAK examine of KSI-501 in moist AMD is actively enrolling sufferers.
KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein. Kodiak is growing KSI-101 for the remedy of retinal inflammatory illnesses, as at present there aren’t any accessible intravitreal biologic therapies addressing the spectrum of inflammatory situations of the retina. The Part 1b APEX examine of KSI-101 is actively enrolling sufferers, as a precursor to activating the Part 2b/3 PEAK and PINNACLE research in sufferers with macular edema secondary to irritation (MESI).
For extra info, please go to www.kodiak.com.
Kodiak ®, Kodiak Sciences ®, ABC™, ABC Platform™ and the Kodiak emblem are registered logos or logos of Kodiak Sciences Inc. in varied world jurisdictions.
